These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 17233546)

  • 1. Patient adherence to osteoporosis medications: problems, consequences and management strategies.
    Papaioannou A; Kennedy CC; Dolovich L; Lau E; Adachi JD
    Drugs Aging; 2007; 24(1):37-55. PubMed ID: 17233546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of adherence to osteoporosis treatment in clinical practice.
    Rossini M; Bianchi G; Di Munno O; Giannini S; Minisola S; Sinigaglia L; Adami S;
    Osteoporos Int; 2006; 17(6):914-21. PubMed ID: 16538553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
    Lee S; Glendenning P; Inderjeeth CA
    Osteoporos Int; 2011 Mar; 22(3):741-53. PubMed ID: 20589368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of osteoporosis in women intolerant of oral bisphosphonates.
    Aspray TJ; Francis RM
    Maturitas; 2012 Jan; 71(1):76-8. PubMed ID: 22079368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.
    Copher R; Buzinec P; Zarotsky V; Kazis L; Iqbal SU; Macarios D
    Curr Med Res Opin; 2010 Apr; 26(4):777-85. PubMed ID: 20095797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
    Danese MD; Badamgarav E; Bauer DC
    J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy].
    García-Hernández P; Carranza-Lira S; Motta-Martínez E
    Ginecol Obstet Mex; 2010 Jun; 78(6):322-8. PubMed ID: 20939245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient treatment preferences for osteoporosis.
    Fraenkel L; Gulanski B; Wittink D
    Arthritis Rheum; 2006 Oct; 55(5):729-35. PubMed ID: 17013870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
    Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW
    Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations regarding adherence of anti-osteoporosis therapy.
    Lagari VS; McAninch E; Baim S
    Postgrad Med; 2015 Jan; 127(1):92-8. PubMed ID: 25526234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to prevent glucocorticoid-induced osteoporosis.
    Dore RK
    Cleve Clin J Med; 2010 Aug; 77(8):529-36. PubMed ID: 20682515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.
    Ringe JD; Schacht E
    Rheumatol Int; 2007 Dec; 28(2):103-11. PubMed ID: 17668216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative Medical Management of Spine Surgery Patients With Osteoporosis.
    Lubelski D; Choma TJ; Steinmetz MP; Harrop JS; Mroz TE
    Neurosurgery; 2015 Oct; 77 Suppl 4():S92-7. PubMed ID: 26378362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-related problems in patients with osteoporosis.
    Ilić D; Bukumirić Z; Janković S
    Vojnosanit Pregl; 2016 Mar; 73(3):261-5. PubMed ID: 27295911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The influence of bisphosphonates on fracture healing].
    Seebach C; Kurth A; Marzi I
    Orthopade; 2007 Feb; 36(2):136-40. PubMed ID: 17242960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
    Gold DT; Alexander IM; Ettinger MP
    Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.